Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.58 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MGAM | O43451 | 2/20 | 0.47 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | SI | P14410 | 2/20 | 0.47 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3463660 | 0.81 | SLC9A1 (0.57) | EGLN3RAB9AMAPTNPC1MGAM | |
| SCHEMBL5388055 | 0.80 | PLA2G4A (0.43) | EGLN3PLA2G4AFFAR1FFAR4RAB9A | |
| SCHEMBL7377696 | 0.79 | MAPT (0.46) | PLA2G4ARAB9AMAPTNPC1MGAM | |
| SCHEMBL15061398 | 0.78 | PLA2G4A (0.56) | PLA2G4ARAB9AMAPTNPC1 | |
| SCHEMBL17125454 | 0.76 | RAB9A (0.55) | RAB9AMAPTNPC1MGAMAMY1A | |
| SCHEMBL16761691 | 0.74 | LTA4H (0.48) | PLA2G4ARAB9AMAPTNPC1MGAM | |
| SCHEMBL6885340 | 0.74 | EGLN3 (1.00) | EGLN3RAB9AMAPTNPC1MGAM | |
| SCHEMBL1775885 | 0.74 | RAB9A (0.61) | EGLN3PLA2G4ARAB9AMAPTNPC1 | |
| SCHEMBL6743169 | 0.73 | TSHR (0.51) | RAB9AMAPTNPC1 | |
| Hydrochloric Acid SCHEMBL31714030 | 0.73 | EGLN3 (0.97) | EGLN3RAB9AMAPTNPC1MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | claimed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | claimed |
| CN-1735408-A | Receptor function controlling agent | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-15 | — | — | CN | claimed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | claimed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| CN-1735408-A | Receptor function controlling agent | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-15 | — | — | CN | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | EGLN3 1964/4885PLA2G4A 2932/4885FFAR1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.